StreetInsider.com News Articles

Form 8-K MEDICINOVA INC For: Feb 20

Fri, 20 Feb 2026 06:25:00 -0500

si-local-file:///var/storage/secattach/20260220/26032661.html

Form 8-K MEDICINOVA INC For: Feb 20

Fri, 20 Feb 2026 06:25:00 -0500

si-local-file:///var/storage/secattach/20260220/26032661.html

MediciNova enrolls 100 patients in ALS drug expanded access study

Thu, 29 Jan 2026 18:01:03 -0500

MediciNova Inc. (NASDAQ: MNOV) announced that 100 patients have enrolled in its SEANOBI expanded access program evaluating MN-166 (ibudilast) for amyotrophic lateral sclerosis treatment, representing 50% of the planned 200-patient enrollment.

The study operates across 12 activated sites in the United States as of January 2026. The SEANOBI program receives funding through a $22 million grant from the National Institute of Neurological Disorders and Stroke under the ACT for ALS initiative.

The expanded access program provides MN-166 treatment to ALS patients who cannot participate in randomized clinical trials while collecting biomarker and clinical outcome data. The program aims to gather real-world evidence

MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients

Thu, 29 Jan 2026 18:00:00 -0500

LA JOLLA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that as of the end of January 2026, 12 sites in the US are activated and 100 patients have been enrolled in the SEANOBI study (Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers in ALS; NCT 06743776) representing 50% of the planned 200-enrollment, evaluating MN‑166 (ibudilast) in patients with amyotrophic lateral sclerosis (ALS).

Dr. Yuichi Iwaki, President and

MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients

Thu, 29 Jan 2026 18:00:00 -0500

Dr. Yuichi Iwaki, President and

Form 4 MEDICINOVA INC For: Jan 16 Filed by: Matsuda Kazuko

Tue, 20 Jan 2026 17:05:00 -0500

si-local-file:///var/storage/secattach/20260120/25869180.html

Form 4 MEDICINOVA INC For: Jan 16 Filed by: Matsuda Kazuko

Tue, 20 Jan 2026 17:05:00 -0500

si-local-file:///var/storage/secattach/20260120/25869180.html

Form 4 MEDICINOVA INC For: Jan 16 Filed by: IWAKI YUICHI

Tue, 20 Jan 2026 17:04:00 -0500

si-local-file:///var/storage/secattach/20260120/25869166.html

Form 4 MEDICINOVA INC For: Jan 16 Filed by: IWAKI YUICHI

Tue, 20 Jan 2026 17:04:00 -0500

si-local-file:///var/storage/secattach/20260120/25869166.html

2026 New Year’s Greetings from the CEO

Tue, 06 Jan 2026 09:00:00 -0500

LA JOLLA, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) provides shareholders a corporate update in the following Letter to Stockholders from CEO Yuichi Iwaki, M.D., Ph.D.

Dear Fellow Shareholders,

The year 2025 was marked by global uncertainty, with accelerating inflation, evolving U.S. trade policies under the new administration, and persistent geopolitical risks. Despite these challenges, MediciNova achieved significant milestones, including completion of patient enrollment in three clinical trials and the launch of

2026 New Year’s Greetings from the CEO

Tue, 06 Jan 2026 09:00:00 -0500

Dear Fellow Shareholders,

Lucid Capital Markets Starts MediciNova (MNOV) at Buy

Mon, 05 Jan 2026 06:36:36 -0500

Lucid Capital Markets initiates coverage on MediciNova (NASDAQ: MNOV) with a Buy rating and a price target of $11.00.

For an analyst ratings summary and ratings history on MediciNova click here. For more ratings news on MediciNova click here.

Shares of MediciNova closed at $1.33 yesterday.

MediciNova enters $50 million equity distribution agreement with Lucid

Tue, 30 Dec 2025 07:55:28 -0500

MediciNova Inc. (NASDAQ: MNOV) entered into an equity distribution agreement with Lucid Capital Markets LLC on December 29, 2025, to sell shares of common stock through an at-the-market offering with a maximum aggregate offering price of $50 million.

Under the sales agreement, Lucid Capital Markets will act as sales agent and may sell the common stock by methods deemed to be an at-the-market offering as defined in Rule 415(a)(4) under the Securities Act of 1933. The company will designate the maximum amount of common stock to be sold in any placement under the agreement.

The agent has agreed to use commercially reasonable

MediciNova enters $50 million equity distribution agreement with Lucid

Tue, 30 Dec 2025 07:55:28 -0500

The agent has agreed to use commercially reasonable

Form 424B5 MEDICINOVA INC

Tue, 30 Dec 2025 07:55:00 -0500

si-local-file:///var/storage/secattach/20251230/25788134.html

Form 424B5 MEDICINOVA INC

Tue, 30 Dec 2025 07:55:00 -0500

si-local-file:///var/storage/secattach/20251230/25788134.html

Form 8-K MEDICINOVA INC For: Dec 29

Tue, 30 Dec 2025 07:53:00 -0500

si-local-file:///var/storage/secattach/20251230/25788133.html

Form 8-K MEDICINOVA INC For: Dec 29

Tue, 30 Dec 2025 07:53:00 -0500

si-local-file:///var/storage/secattach/20251230/25788133.html

MediciNova completes patient enrollment for neuropathy prevention study

Thu, 18 Dec 2025 06:01:17 -0500

MediciNova Inc. (NASDAQ: MNOV) announced completion of patient enrollment in a Phase 2 clinical trial evaluating MN-166 (ibudilast) for preventing chemotherapy-induced peripheral neuropathy in patients with metastatic colorectal cancer.

The randomized, placebo-controlled OXTOX study enrolled 100 patients across 11 clinical sites in Australia. The investigator-initiated trial is led by Dr. Janette Vardy and Dr. Haryana Dhillon.

Study participants will continue chemotherapy along with either MN-166 or placebo until disease progression or unacceptable side effects occur. The study will conclude when the final patient reaches six months post-chemotherapy. The company expects top-line data may be available in 2026.

MN-166 is a small molecule compound

MediciNova completes patient enrollment for neuropathy prevention study

Thu, 18 Dec 2025 06:01:17 -0500

The randomized, placebo-controlled OXTOX study enrolled 100 patients across 11 clinical sites in Australia. The investigator-initiated trial is led by Dr. Janette Vardy and Dr. Haryana Dhillon.

MN-166 is a small molecule compound

MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

Thu, 18 Dec 2025 06:00:00 -0500

LA JOLLA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful completion of patient enrollment in the randomized, placebo-controlled Phase 2 clinical trial, the OXTOX study (Oxaliplatin Neurotoxicity study in patients with metastatic colorectal cancer). This study, an investigator-initiated clinical trial led by Dr. Janette Vardy and Dr. Haryana Dhillon, is evaluating MN-166 (ibudilast) for the prevention of chemotherapy-induced peripheral neuropathy in patients with metastatic colorectal cancer. A total of 100

MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

Thu, 18 Dec 2025 06:00:00 -0500

Form EFFECT MEDICINOVA INC

Fri, 12 Dec 2025 06:03:00 -0500

si-local-file:///var/storage/secattach/20251212/25731875.html

Form EFFECT MEDICINOVA INC

Fri, 12 Dec 2025 06:03:00 -0500

si-local-file:///var/storage/secattach/20251212/25731875.html

MediciNova completes enrollment in ALS drug trial with 234 patients

Mon, 08 Dec 2025 06:00:16 -0500

MediciNova Inc. (NASDAQ: MNOV) announced completion of enrollment in its Phase 2b/3 clinical trial testing MN-166 (ibudilast) for amyotrophic lateral sclerosis treatment. The COMBAT-ALS study enrolled 234 participants, with enrollment completed in September 2025.

The company presented baseline patient characteristics at the 36th International Symposium on ALS/MND held December 5-7, 2025 in San Diego. The enrolled participants included 86 females (36.8%) and 148 males (63.2%), with a mean age of 60.6 years at screening.

The racial distribution showed 90.2% Caucasian patients, 5.1% Asian, 1.3% African American, 0.4% Native Hawaiian or Other Pacific Islander, 0.4% American Indian or Alaskan Native, and 2.6% other.